# Align Technology Inc: overview

ALGN · Nasdaq · CIK 1097149 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/algn.md) · [Financials](/companies/algn/financials.md) · [Filings](/companies/algn/filings.md) · [Insiders](/companies/algn/insiders.md)

Latest reported revenue: [$1.06bn](/filings/0001097149-26-000060.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001097149-26-000060).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [978](/filings/0001097149-25-000079.md) | [995 d](/filings/0001097149-26-000014.md) | [979](/filings/0001097149-26-000040.md) | [1,012](/filings/0001097149-26-000060.md) | [996](/filings/0001097149-25-000079.md) | [1,048 d](/filings/0001097149-26-000014.md) | [1,040](/filings/0001097149-26-000040.md) | [1,056](/filings/0001097149-26-000060.md) |
| Gross margin | % | [69.7%](/filings/0001097149-25-000079.md) | [70.0% d](/filings/0001097149-26-000014.md) | [69.5%](/filings/0001097149-26-000040.md) | [69.9%](/filings/0001097149-26-000060.md) | [64.2%](/filings/0001097149-25-000079.md) | [65.3% d](/filings/0001097149-26-000014.md) | [70.8%](/filings/0001097149-26-000040.md) | [71.7%](/filings/0001097149-26-000060.md) |
| Operating margin | % | [16.6%](/filings/0001097149-25-000079.md) | [14.5% d](/filings/0001097149-26-000014.md) | [13.4%](/filings/0001097149-26-000040.md) | [16.1%](/filings/0001097149-26-000060.md) | [9.7%](/filings/0001097149-25-000079.md) | [14.8% d](/filings/0001097149-26-000014.md) | [13.6%](/filings/0001097149-26-000040.md) | [14.6%](/filings/0001097149-26-000060.md) |
| Net margin | % | [11.9%](/filings/0001097149-25-000079.md) | [10.4% d](/filings/0001097149-26-000014.md) | [9.5%](/filings/0001097149-26-000040.md) | [12.3%](/filings/0001097149-26-000060.md) | [5.7%](/filings/0001097149-25-000079.md) | [13.0% d](/filings/0001097149-26-000014.md) | [10.8%](/filings/0001097149-26-000040.md) | [10.3%](/filings/0001097149-26-000060.md) |
| Diluted EPS | $ per share | [1.55](/filings/0001097149-25-000079.md) | not reported | [1.27](/filings/0001097149-26-000040.md) | [1.72](/filings/0001097149-26-000060.md) | [0.78](/filings/0001097149-25-000079.md) | not reported | [1.57](/filings/0001097149-26-000040.md) | [1.51](/filings/0001097149-26-000060.md) |
| Free cash flow | $m | [234 d](/filings/0001097149-25-000079.md) | [263 d](/filings/0001097149-26-000014.md) | [27.4](/filings/0001097149-26-000040.md) | [107 d](/filings/0001097149-26-000060.md) | [169 d](/filings/0001097149-25-000079.md) | [187 d](/filings/0001097149-26-000014.md) | [120](/filings/0001097149-26-000040.md) | [157 d](/filings/0001097149-26-000060.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [3,953](/filings/0001097149-24-000011.md) | [3,735](/filings/0001097149-25-000012.md) | [3,862](/filings/0001097149-26-000014.md) | [3,999](/filings/0001097149-26-000014.md) | [4,035](/filings/0001097149-26-000014.md) |
| Gross margin | % | [74.3%](/filings/0001097149-24-000011.md) | [70.5%](/filings/0001097149-25-000012.md) | [70.1%](/filings/0001097149-26-000014.md) | [70.0%](/filings/0001097149-26-000014.md) | [67.2%](/filings/0001097149-26-000014.md) |
| Operating margin | % | [24.7%](/filings/0001097149-24-000011.md) | [17.2%](/filings/0001097149-25-000012.md) | [16.7%](/filings/0001097149-26-000014.md) | [15.2%](/filings/0001097149-26-000014.md) | [13.5%](/filings/0001097149-26-000014.md) |
| Net margin | % | [19.5%](/filings/0001097149-24-000011.md) | [9.7%](/filings/0001097149-25-000012.md) | [11.5%](/filings/0001097149-26-000014.md) | [10.5%](/filings/0001097149-26-000014.md) | [10.2%](/filings/0001097149-26-000014.md) |
| Diluted EPS | $ per share | [9.69](/filings/0001097149-24-000011.md) | [4.61](/filings/0001097149-25-000012.md) | [5.81](/filings/0001097149-26-000014.md) | [5.62](/filings/0001097149-26-000014.md) | [5.65](/filings/0001097149-26-000014.md) |
| Free cash flow | $m | [771](/filings/0001097149-24-000011.md) | [277](/filings/0001097149-25-000012.md) | [608](/filings/0001097149-26-000014.md) | [623](/filings/0001097149-26-000014.md) | [491](/filings/0001097149-26-000014.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/algn/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $745.4m | 4,419,366 |  | Added +129,442 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $742.3m | 4,401,313 |  | Added +12,194 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $684.8m | 4,060,032 |  | Added +1,359,673 |
| [Capital International Investors](/funds/1562230.md) | 2026-06-30 | $682.3m | 4,045,561 |  | Added +236,359 |
| [Capital World Investors](/funds/1422849.md) | 2026-06-30 | $577.2m | 3,422,385 |  | Reduced −649,911 |
| [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $568.8m | 3,372,760 |  | Added +1,576,509 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $528.2m | 3,131,764 |  | Reduced −19,019 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $431.5m | 2,558,512 |  | Added +42,258 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $378.2m | 2,245,315 |  | Added +454,611 |
| [Ninety One UK Ltd](/funds/1418329.md) | 2026-06-30 | $372.7m | 2,209,791 |  | Reduced −18,423 |

## Recent filings

[All 1,420 filings](/companies/algn/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-31 | 16:05 ET | [8-K](/filings/0001097149-26-000065.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001097149-26-000065 |
| 2026-08-05 | 16:08 ET | [10-Q](/filings/0001097149-26-000060.md) | Quarterly report, period 2026-06-30 | 0001097149-26-000060 |
| 2026-07-29 | 16:15 ET | [8-K](/filings/0001097149-26-000056.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001097149-26-000056 |
| 2026-07-29 | 16:04 ET | [8-K](/filings/0001097149-26-000054.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001097149-26-000054 |
| 2026-07-09 | 20:29 ET | [8-K](/filings/0001097149-26-000050.md) | 5.02 Departure or appointment of officers or directors | 0001097149-26-000050 |
| 2026-06-22 | 21:02 ET | [8-K](/filings/0001097149-26-000048.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001097149-26-000048 |
| 2026-05-20 | 16:28 ET | [8-K](/filings/0001097149-26-000042.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001097149-26-000042 |
| 2026-05-06 | 16:43 ET | [10-Q](/filings/0001097149-26-000040.md) | Quarterly report, period 2026-03-31 | 0001097149-26-000040 |
| 2026-05-01 | 19:51 ET | [8-K](/filings/0001097149-26-000036.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001097149-26-000036 |
| 2026-04-29 | 16:04 ET | [8-K](/filings/0001097149-26-000033.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001097149-26-000033 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001097149-26-000014.md), filed Feb 27, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/e30f8bea-ae7e-44f8-b30f-bf634881ee57)

## About the filer

- CIK: 1097149
- Tickers: ALGN
- Exchange: Nasdaq
- SIC code: 3842 Orthopedic, Prosthetic & Surgical Appliances & Supplies
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:33 ET. No prices; not investment advice.